Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Self-citationA decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Self-citationInhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Self-citationHDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritson, G. P., Nedelsky, N. B., Schwartz, S. L., DiProspero, N. A., Knight, M. A., Schuldiner, O., et al. (2007) · Nature · doi:10.1038/nature05853 · Cited by 1,234
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,139
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,110
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Role of the histone deacetylase complex in acute promyelocytic leukaemia
Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., & Evans, R. M. (1998) · Nature · doi:10.1038/35895 · Cited by 1,062
Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy
Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949
Deacetylase inhibition promotes the generation and function of regulatory T cells
Tao, R., de Zoeten, E. F., Özkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I., et al. (2007) · Nature Medicine · doi:10.1038/nm1652 · Cited by 924
An epigenetic blockade of cognitive functions in the neurodegenerating brain
Gräff, J., Rei, D., Guan, J.-S., Wang, W.-Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., et al. (2012) · Nature · doi:10.1038/nature10849 · Cited by 853
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
Self-citationRational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801
Dompierre, J. P., Godin, J. D., Charrin, B. C., Cordelières, F. P., King, S. J., Humbert, S., & Saudou, F. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0037-07.2007 · Cited by 792
n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells
RIGGS, M. G., WHITTAKER, R. G., NEUMANN, J. R., & INGRAM, V. M. (1977) · Nature · doi:10.1038/268462a0 · Cited by 787
Di Croce, L., Raker, V. A., Corsaro, M., Fazi, F., Fanelli, M., Faretta, M., Fuks, F., Coco, F. L., Kouzarides, T., Nervi, C., et al. (2002) · Science · doi:10.1126/science.1065173 · Cited by 787
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755
Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00429-4 · Cited by 754
The acetylation of tau inhibits its function and promotes pathological tau aggregation
Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Nature Communications · doi:10.1038/ncomms1255 · Cited by 724
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
Multiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells
Leder, A., & Leder, P. (1975) · Cell · doi:10.1016/0092-8674(75)90107-5 · Cited by 650
Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
Shao, Y., Gao, Z., Marks, P. A., & Jiang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408345102 · Cited by 605
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfı́, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706487104 · Cited by 566
Histone deacetylases as regulators of inflammation and immunity
Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., & Sweet, M. J. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.001 · Cited by 546
Peart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 539
Self-citationInsinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm1160 · Cited by 516
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 509
Delcuve, G. P., Khan, D. H., & Davie, J. R. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-5 · Cited by 505
Ungerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension
Kaminskas, E., Farrell, A. T., Wang, Y.-C., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-3-176 · Cited by 490
Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., Kofler, R., Smyth, M. J., & Johnstone, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191208598 · Cited by 488
Self-citationBullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2014) · Nature Medicine · doi:10.1038/nm.3489 · Cited by 488
(2003) · PubMed · Cited by 465
Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 459
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Villagra, A., Cheng, F., Wang, H.-W., Suarez, I., Glozak, M., Maurin, M., Nguyen, D., Wright, K. L., Atadja, P. W., Bhalla, K., et al. (2009) · Nature Immunology · doi:10.1038/ni.1673 · Cited by 455
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S. L., & Gottesfeld, J. M. (2006) · Nature Chemical Biology · doi:10.1038/nchembio815 · Cited by 442
Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes
Kaminskas, E., Farrell, A., Abraham, S., Baird, A., Hsieh, L.-S., Lee, S.-L., Leighton, J. K., Patel, H., Rahman, A., Sridhara, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2135 · Cited by 423
Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation
Jeong, H., Then, F., Melia, T. J., Mazzulli, J. R., Cui, L., Savas, J. N., Voisine, C., Paganetti, P., Tanese, N., Hart, A. C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.018 · Cited by 419
HDACs link the DNA damage response, processing of double-strand breaks and autophagy
Robert, T., Vanoli, F., Chiolo, I., Shubassi, G., Bernstein, K. A., Rothstein, R., Botrugno, O. A., Parazzoli, D., Oldani, A., Minucci, S., et al. (2011) · Nature · doi:10.1038/nature09803 · Cited by 412
Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease.
Brady, R. O., Kanfer, J. N., Bradley, R. M., & Shapiro, D. (1966) · Journal of Clinical Investigation · doi:10.1172/jci105417 · Cited by 411
Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205108 · Cited by 400
Targeting Epigenetic Readers in Cancer
Dawson, M. A., Kouzarides, T., & Huntly, B. J. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1112635 · Cited by 397
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Lobera, M., Madauss, K. P., Pohlhaus, D. T., Wright, Q. G., Trocha, M., Schmidt, D. R., Baloglu, E., Trump, R. P., Head, M. S., Hofmann, G. A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1223 · Cited by 376
Hdac3 is essential for the maintenance of chromatin structure and genome stability
Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353
Licht, J., Chomienne, C., Goy, A., Chen, A., Scott, A., Head, D., Michaux, J., Wu, Y., DeBlasio, A., & Miller, W. J. (1995) · Blood · doi:10.1182/blood.v85.4.1083.bloodjournal8541083 · Cited by 343
Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease
Govindarajan, N., Rao, P., Burkhardt, S., Sananbenesi, F., Schlüter, O. M., Bradke, F., Lu, J., & Fischer, A. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201923 · Cited by 342
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
Simões-Pires, C., Zwick, V., Nurisso, A., Schenker, E., Carrupt, P.-A., & Cuendet, M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-7 · Cited by 341
VanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.35 · Cited by 333
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia
Blum, W., Klisovic, R. B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4169 · Cited by 315
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M., Olzscha, H., & La Thangue, N. B. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310
Cook, C., Carlomagno, Y., Gendron, T. F., Dunmore, J., Scheffel, K., Stetler, C., Davis, M., Dickson, D., Jarpe, M., DeTure, M., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt402 · Cited by 309
Montgomery, R. L., Hsieh, J., Barbosa, A. C., Richardson, J. A., & Olson, E. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902750106 · Cited by 306
Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1766-x · Cited by 303
The 8;21 translocation in leukemogenesis
Peterson, L. F., & Zhang, D.-E. (2004) · Oncogene · doi:10.1038/sj.onc.1207727 · Cited by 302
Williams, S. R., Aldred, M. A., Der Kaloustian, V. M., Halal, F., Gowans, G., McLeod, D. R., Zondag, S., Toriello, H. V., Magenis, R. E., & Elsea, S. H. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.07.011 · Cited by 302
Perrine, S. P., Hermine, O., Small, T., Suarez, F., O'Reilly, R., Boulad, F., Fingeroth, J., Askin, M., Levy, A., Mentzer, S. J., et al. (2007) · Blood · doi:10.1182/blood-2006-01-024703 · Cited by 297
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression
Yamaguchi, T., Cubizolles, F., Zhang, Y., Reichert, N., Kohler, H., Seiser, C., & Matthias, P. (2010) · Genes & Development · doi:10.1101/gad.552310 · Cited by 291
Rad23 Promotes the Targeting of Proteolytic Substrates to the Proteasome
Chen, L., & Madura, K. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.13.4902-4913.2002 · Cited by 290
Deregulation of HDAC1 by p25/Cdk5 in Neurotoxicity
Kim, D., Frank, C. L., Dobbin, M. M., Tsunemoto, R. K., Tu, W., Peng, P. L., Guan, J.-S., Lee, B.-H., Moy, L. Y., Giusti, P., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.015 · Cited by 286
Nusinzon, I., & Horvath, C. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2433987100 · Cited by 282
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
Yu, W., Chory, E. J., Wernimont, A. K., Tempel, W., Scopton, A., Federation, A., Marineau, J. J., Qi, J., Barsyte-Lovejoy, D., Yi, J., et al. (2012) · Nature Communications · doi:10.1038/ncomms2304 · Cited by 281
A phosphorylation-acetylation switch regulates STAT1 signaling
Krämer, O. H., Knauer, S. K., Greiner, G., Jandt, E., Reichardt, S., Gührs, K.-H., Stauber, R. H., Böhmer, F. D., & Heinzel, T. (2009) · Genes & Development · doi:10.1101/gad.479209 · Cited by 281
Nimmanapalli, R., Fuino, L., Bali, P., Gasparetto, M., Glozak, M. A., Tao, J., Moscinski, L. C., Smith, C. A., Wu, J., Jove, R., et al. (2003) · PubMed · Cited by 276
Tedeschini, E., Levkovitz, Y., Iovieno, N., Ameral, V. E., Nelson, J. C., & Papakostas, G. I. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06531 · Cited by 269
Reddy, P., Maeda, Y., Hotary, K., Liu, C., Reznikov, L. L., Dinarello, C. A., & Ferrara, J. L. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400380101 · Cited by 266
Reddy, P., Sun, Y., Toubai, T., Duran-Struuck, R., Clouthier, S. G., Weisiger, E., Maeda, Y., Tawara, I., Krijanovski, O., Gatza, E., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34712 · Cited by 265
Fuino, L., Bali, P., Wittmann, S., Donapaty, S., Guo, F., Yamaguchi, H., Wang, H., Atadja, P. W., & Bhalla, K. N. (2003) · PubMed · Cited by 263
Ryu, H., Lee, J., Olofsson, B. A., Mwidau, A., Deodoglu, A., Escudero, M., Flemington, E., Azizkhan-Clifford, J., Ferrante, R. J., & Ratan, R. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737363100 · Cited by 261
Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3 + T-Regulatory Cells
de Zoeten, E. F., Wang, L., Butler, K., Beier, U. H., Akimova, T., Sai, H., Bradner, J. E., Mazitschek, R., Kozikowski, A. P., Matthias, P., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05155-11 · Cited by 258
Qiu, L., Burgess, A., Fairlie, D. P., Leonard, H., Parsons, P. G., & Gabrielli, B. G. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.6.2069 · Cited by 249
Qian, C., Lai, C.-J., Bao, R., Wang, D.-G., Wang, J., Xu, G.-X., Atoyan, R., Qu, H., Yin, L., Samson, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0055 · Cited by 248
Role of the Polycomb Repressive Complex 2 in Acute Promyelocytic Leukemia
Villa, R., Pasini, D., Gutierrez, A., Morey, L., Occhionorelli, M., Viré, E., Nomdedeu, J. F., Jenuwein, T., Pelicci, P. G., Minucci, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.009 · Cited by 247
Jaboin, J. J., Wild, J., Hamidi, H., Khanna, C., Kim, C. J., Robey, R. W., Bates, S. E., & Thiele, C. J. (2002) · PubMed · Cited by 247
Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer
Thurn, K. T., Thomas, S., Moore, A., & Munster, P. N. (2011) · Future Oncology · doi:10.2217/fon.11.2 · Cited by 246
Dai, Y., Rahmani, M., Dent, P., & Grant, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5429-5444.2005 · Cited by 245
Activity-based probes for proteomic profiling of histone deacetylase complexes
Salisbury, C. M., & Cravatt, B. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608659104 · Cited by 243
Inhibition of HDAC9 Increases T Regulatory Cell Function and Prevents Colitis in Mice
de Zoeten, E. F., Wang, L., Sai, H., Dillmann, W. H., & Hancock, W. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.037 · Cited by 239
Trials with ‘epigenetic’ drugs: An update
Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 237
An Essential Role for Histone Deacetylase 4 in Synaptic Plasticity and Memory Formation
Kim, M.-S., Akhtar, M. W., Adachi, M., Mahgoub, M., Bassel-Duby, R., Kavalali, E. T., Olson, E. N., & Monteggia, L. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2089-12.2012 · Cited by 235
Targeting tumor angiogenesis with histone deacetylase inhibitors
Ellis, L., Hammers, H., & Pili, R. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.11.012 · Cited by 232
Badros, A., Burger, A. M., Philip, S., Niesvizky, R., Kolla, S. S., Goloubeva, O., Harris, C., Zwiebel, J., Wright, J. J., Espinoza-Delgado, I., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2850 · Cited by 231
P-Glycoprotein Substrates and Antagonists Cluster into Two Distinct Groups
Scala, S., Akhmed, N., Rao, U. S., Paull, K., Lan, L.-B., Dickstein, B., Lee, J.-S., Elgemeie, G. H., Stein, W. D., & Bates, S. E. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.6.1024 · Cited by 229
Chen, L., Shinde, U., Ortolan, T. G., & Madura, K. (2001) · EMBO reports · doi:10.1093/embo-reports/kve203 · Cited by 218
Rational Combinations Using HDAC Inhibitors
Bots, M., & Johnstone, R. W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2786 · Cited by 217
Self-citationDifferentiation of NUT Midline Carcinoma by Epigenomic Reprogramming
Schwartz, B. E., Hofer, M. D., Lemieux, M. E., Bauer, D. E., Cameron, M. J., West, N. H., Agoston, E. S., Reynoird, N., Khochbin, S., Ince, T. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3513 · Cited by 217
HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse Model
Rai, M., Soragni, E., Jenssen, K., Burnett, R., Herman, D., Coppola, G., Geschwind, D. H., Gottesfeld, J. M., & Pandolfo, M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001958 · Cited by 214
Chang, H.-M., Paulson, M., Holko, M., Rice, C. M., Williams, B. R. G., Marié, I., & Levy, D. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400567101 · Cited by 212
Lai, C.-J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D.-G., Yin, L., Samson, M., Forrester, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3360 · Cited by 212
Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death
Gammoh, N., Lam, D., Puente, C., Ganley, I., Marks, P. A., & Jiang, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204429109 · Cited by 211
Liu, Y.-L., Yang, P.-M., Shun, C.-T., Wu, M.-S., Weng, J.-R., & Chen, C.-C. (2010) · Autophagy · doi:10.4161/auto.6.8.13365 · Cited by 207
Namdar, M., Perez, G., Ngo, L., & Marks, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013754107 · Cited by 203
Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R., & Pili, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030815 · Cited by 202
Lindemann, R. K., Newbold, A., Whitecross, K. F., Cluse, L. A., Frew, A. J., Ellis, L., Williams, S., Wiegmans, A. P., Dear, A. E., Scott, C. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702294104 · Cited by 199
Self-citationYeo, W., Chung, H. C., Chan, S. L., Wang, L. Z., Lim, R., Picus, J., Boyer, M., Mo, F. K. F., Koh, J., Rha, S. Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2395 · Cited by 199
Histone Deacetylase Inhibitors In Inflammatory Disease
Halili, M., Andrews, M., Sweet, M., & Fairlie, D. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609788085250 · Cited by 198
Rego, E. M., He, L.-Z., Warrell, R. P., Wang, Z.-G., & Pandolfi, P. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180290497 · Cited by 194
HDAC6 Deacetylase Activity Links the Tubulin Cytoskeleton with Immune Synapse Organization
Serrador, J. M., Cabrero, J. R., Sancho, D., Mittelbrunn, M., Urzainqui, A., & Sánchez-Madrid, F. (2004) · Immunity · doi:10.1016/s1074-7613(04)00078-0 · Cited by 193
Tubastatin A/ACY-1215 Improves Cognition in Alzheimer's Disease Transgenic Mice
Zhang, L., Liu, C., Wu, J., Tao, J.-J., Sui, X.-L., Yao, Z.-G., Xu, Y.-F., Huang, L., Zhu, H., Sheng, S.-L., et al. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140066 · Cited by 192
Pazolli, E., Alspach, E., Milczarek, A., Prior, J., Piwnica-Worms, D., & Stewart, S. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3386 · Cited by 192
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
Bolden, J. E., Shi, W., Jankowski, K., Kan, C.-Y., Cluse, L., Martin, B. P., MacKenzie, K. L., Smyth, G. K., & Johnstone, R. W. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.9 · Cited by 192
Self-citationHistone deacetylases and the immunological network: implications in cancer and inflammation
Villagra, A., Sotomayor, E. M., & Seto, E. (2010) · Oncogene · doi:10.1038/onc.2009.334 · Cited by 192
Requirement of Histone Deacetylase Activity for Signaling by STAT1
Klampfer, L., Huang, J., Swaby, L.-A., & Augenlicht, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401359200 · Cited by 189
Leng, Y., & Chuang, D.-M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0096-06.2006 · Cited by 188
Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
Setiadi, A. F., Omilusik, K., David, M. D., Seipp, R. P., Hartikainen, J., Gopaul, R., Choi, K. B., & Jefferies, W. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5270 · Cited by 184
Bandukwala, H. S., Gagnon, J., Togher, S., Greenbaum, J. A., Lamperti, E. D., Parr, N. J., Molesworth, A. M. H., Smithers, N., Lee, K., Witherington, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212264109 · Cited by 181
AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML
Licht, J. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204593 · Cited by 180
Xu, W., Ngo, L., Perez, G., Dokmanovic, M., & Marks, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607518103 · Cited by 179
Backs, J., Backs, T., Bezprozvannaya, S., McKinsey, T. A., & Olson, E. N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01611-07 · Cited by 179
Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction
Shi, L., Cui, S., Engel, J. D., & Tanabe, O. (2013) · Nature Medicine · doi:10.1038/nm.3101 · Cited by 172
Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis
Kwon, H. J., Kim, M. S., Kim, M. J., Nakajima, H., & Kim, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.1602 · Cited by 171
Akhtar, M. W., Raingo, J., Nelson, E. D., Montgomery, R. L., Olson, E. N., Kavalali, E. T., & Monteggia, L. M. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0097-09.2009 · Cited by 170
Fantin, V. R., Loboda, A., Paweletz, C. P., Hendrickson, R. C., Pierce, J. W., Roth, J. A., Li, L., Gooden, F., Korenchuk, S., Hou, X. S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6091 · Cited by 170
Jia, H., Pallos, J., Jacques, V., Lau, A., Tang, B., Cooper, A., Syed, A., Purcell, J., Chen, Y., Sharma, S., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.016 · Cited by 169
Histone-Deacetylase Inhibitors for the Treatment of Cancer
Lindemann, R. K., Gabrielli, B. G., & Johnstone, R. W. (2004) · Cell Cycle · doi:10.4161/cc.3.6.927 · Cited by 168
Self-citationJochems, J., Boulden, J., Lee, B. G., Blendy, J. A., Jarpe, M., Mazitschek, R., Van Duzer, J. H., Jones, S., & Berton, O. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.207 · Cited by 166
Suzuki, T., Ota, Y., Ri, M., Bando, M., Gotoh, A., Itoh, Y., Tsumoto, H., Tatum, P. R., Mizukami, T., Nakagawa, H., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300837y · Cited by 165
Garcia-Manero, G., Tambaro, F. P., Bekele, N. B., Yang, H., Ravandi, F., Jabbour, E., Borthakur, G., Kadia, T. M., Konopleva, M. Y., Faderl, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3265 · Cited by 163
Genetic syndromes caused by mutations in epigenetic genes
Berdasco, M., & Esteller, M. (2013) · Human Genetics · doi:10.1007/s00439-013-1271-x · Cited by 163
Archin, N. M., Keedy, K. S., Espeseth, A., Dang, H., Hazuda, D. J., & Margolis, D. M. (2009) · AIDS · doi:10.1097/qad.0b013e32832ec1dc · Cited by 162
Ghosh, S. K., Perrine, S. P., Williams, R. M., & Faller, D. V. (2012) · Blood · doi:10.1182/blood-2011-06-362434 · Cited by 160
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2013.231 · Cited by 159
Conti, C., Leo, E., Eichler, G. S., Sordet, O., Martin, M. M., Fan, A. M., Aladjem, M. I., & Pommier, Y. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3028 · Cited by 159
STAT5‐induced Id‐1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPβ
Xu, M. J., Nie, L., Kim, S., & Sun, X. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg094 · Cited by 157
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Khan, O. A., Fotheringham, S. A., Wood, V. H. J., Stimson, L., Zhang, C., Pezzella, F., Duvic, M. A., Kerr, D. J., & Thangue, N. B. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913912107 · Cited by 157
Millward, M., Price, T. J., Townsend, A. R., Sweeney, C. J., Spencer, A. G., Sukumaran, S., Longenecker, A. M., Lee, L., Lay, A., Sharma, G. D., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9766-6 · Cited by 156
Frew, A. J., Lindemann, R. K., Martin, B. P., Clarke, C. J. P., Sharkey, J., Anthony, D. A., Banks, K.-M., Haynes, N. M., Gangatirkar, P., Stanley, K. L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801868105 · Cited by 155
Self-citationKachhap, S. K., Rosmus, N., Collis, S. J., Kortenhorst, M. S. Q., Wissing, M. D., Hedayati, M. A., Shabbeer, S., Mendonca, J., Deangelis, J., Marchionni, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011208 · Cited by 154
The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity
Liu, Y., Cheney, M. D., Gaudet, J., Chruszcz, M., Lukasik, S. M., Sugiyama, D., Lary, J. W., Cole, J. L., Dauter, Z., Minor, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.012 · Cited by 154
Robert, C., & Rassool, F. V. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00003-3 · Cited by 153
Qiu, T., Zhou, L. Q., Zhu, W., Wang, T., Wang, J., Shu, Y., & Liu, P. (2013) · Future Oncology · doi:10.2217/fon.12.173 · Cited by 152
HDAC4 inhibits cell‐cycle progression and protects neurons from cell death
Majdzadeh, N., Wang, L., Morrison, B. E., Bassel‐Duby, R., Olson, E. N., & D’Mello, S. R. (2008) · Developmental Neurobiology · doi:10.1002/dneu.20637 · Cited by 149
Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors
Guerrant, W., Patil, V., Canzoneri, J. C., & Oyelere, A. K. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm200799p · Cited by 149
Langley, B. C., D’Annibale, M. A., Suh, K., Ayoub, I. A., Tolhurst, A. T., Baştan, B., Yang, L., Ko, B., Fisher, M., Cho, S., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3200-07.2008 · Cited by 148
Selenica, M. B., Benner, L., Housley, S. B., Manchec, B., Lee, D. C., Nash, K. R., Kalin, J. H., Bergman, J. A., Kozikowski, A. P., Gordon, M. N., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt241 · Cited by 148
Dovey, O. M., Foster, C. T., Conte, N., Edwards, S. A., Edwards, J. M., Singh, R., Vassiliou, G. S., Bradley, A., & Cowley, S. M. (2013) · Blood · doi:10.1182/blood-2012-07-441949 · Cited by 148
Schroeder, F. A., Lewis, M. C., Fass, D. M., Wagner, F. F., Zhang, Y.-L., Hennig, K. M., Gale, J., Zhao, W.-N., Reis, S., Barker, D. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071323 · Cited by 146
Reduced Body Size and Decreased Intestinal Tumor Rates in HDAC2-Mutant Mice
Zimmermann, S., Kiefer, F., Prudenziati, M., Spiller, C., Hansen, J., Floß, T., Wurst, W., Minucci, S., & Göttlicher, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0312 · Cited by 145
Histone/protein deacetylases and T-cell immune responses
Akimova, T., Beier, U. H., Liu, Y., Wang, L., & Hancock, W. W. (2012) · Blood · doi:10.1182/blood-2011-10-292003 · Cited by 143
Interplay of RUNX1/MTG8 and DNA Methyltransferase 1 in Acute Myeloid Leukemia
Liu, S., Shen, T., Huynh, L., Klisovic, M. I., Rush, L. J., Ford, J. L., Yu, J., Becknell, B., Yu, L., Liu, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4532 · Cited by 142
Munro, J., Barr, N. I., Ireland, H., Morrison, V., & Parkinson, E. K. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.01.017 · Cited by 141
Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells
Petruccelli, L. A., Dupéré-Richer, D., Pettersson, F., Retrouvey, H., Skoulikas, S., & Miller, W. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020987 · Cited by 141
Development of a histone deacetylase 6 inhibitor and its biological effects
Lee, J.-H., Mahendran, A., Yao, Y., Ngo, L., Venta-Perez, G., Choy, M. L., Kim, N., Ham, W.-S., Breslow, R., & Marks, P. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313893110 · Cited by 141
Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors
West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0890 · Cited by 137
Self-citationWillmann, D., Lim, S., Wetzel, S., Metzger, E., Jandausch, A., Wilk, W., Jung, M., Forné, I., Imhof, A., Janzer, A., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27555 · Cited by 135
Bots, M. L., Verbrugge, I., Martin, B. P., Salmon, J. M., Ghisi, M., Baker, A., Stanley, K. L., Shortt, J., Ossenkoppele, G. J., Zuber, J. A., et al. (2014) · Blood · doi:10.1182/blood-2013-03-488114 · Cited by 134
Self-citationSandi, C., Pinto, R. M., Al‐Mahdawi, S., Ezzatizadeh, V., Barnes, G., Jones, S. E., Rusche, J. R., Gottesfeld, J. M., & Pook, M. A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.02.016 · Cited by 133
Histone deacetylase inhibitors and HIV latency
Margolis, D. M. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328341242d · Cited by 133
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance
Santoro, F., Botrugno, O. A., Zuffo, R. D., Pallavicini, I., Matthews, G. M., Cluse, L. A., Barozzi, I., Senese, S., Fornasari, L., Moretti, S., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461988 · Cited by 132
Self-citationGrausenburger, R., Bilić, I., Boucheron, N., Zupkovitz, G., El-Housseiny, L., Tschismarov, R., Zhang, Y., Rembold, M., Gaisberger, M., Hartl, A. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903610 · Cited by 130
Revisiting the differentiation paradigm in acute promyelocytic leukemia
Ablain, J., & de Thé, H. (2011) · Blood · doi:10.1182/blood-2011-02-329367 · Cited by 128
The Role of HDAC6 in Alzheimer's Disease
Zhang, L., Sheng, S., & Qin, C. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120727 · Cited by 127
Loss of Deacetylation Activity of Hdac6 Affects Emotional Behavior in Mice
Fukada, M., Hanai, A., Nakayama, A., Suzuki, T., Miyata, N., Rodriguiz, R. M., Wetsel, W. C., Yao, T., & Kawaguchi, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030924 · Cited by 127
Acetylated Tau Neuropathology in Sporadic and Hereditary Tauopathies
Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., McCarty-Wood, E., Van Deerlin, V. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.04.025 · Cited by 125
Shia, W.-J., Okumura, A. J., Yan, M., Sarkeshik, A., Lo, M., Matsuura, S., Komeno, Y., Zhao, X., Nimer, S. D., Yates, J. R., et al. (2012) · Blood · doi:10.1182/blood-2011-04-347476 · Cited by 124
Kozikowski, A. P., Chen, Y., Gaysin, A. M., Chen, B., D’Annibale, M. A., Suto, C. M., & Langley, B. C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070178x · Cited by 124
Vishwakarma, S., Iyer, L. R., Muley, M. M., Singh, P., Shastry, A., Saxena, A., Kulathingal, J., Vijaykanth, G., Raghul, J., Rajesh, N., et al. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.03.016 · Cited by 124
Cimino, G. G., Lo‐Coco, F., Fenu, S., Travaglini, L., Finolezzi, E., Mancini, M., Nanni, M., Careddu, A., Fazi, F., Padula, F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2726 · Cited by 124
Ellis, L., Bots, M. L., Lindemann, R. K., Bolden, J. E., Newbold, A., Cluse, L. A., Scott, C. L., Strasser, A., Atadja, P. W., Lowe, S. W., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182758 · Cited by 123
Self-citationLee, Y. J., Won, A. J., Lee, J., Jung, J. H., Yoon, S., Lee, B. M., & Kim, H. S. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.5011 · Cited by 123
Bobrowska, A., Paganetti, P., Matthias, P., & Bates, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020696 · Cited by 121
Christiansen, A. J., West, A. C., Banks, K.-M., Haynes, N. M., Teng, M. W. L., Smyth, M. J., & Johnstone, R. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011037108 · Cited by 116
Self-citationTranscriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects
Marshall, G. M., Gherardi, S., Xu, N., Neiron, Z., Trahair, T. N., Scarlett, C. J., Chang, D. K.-F., Liu, P. Y., Jankowski, K., Iraci, N., et al. (2010) · Oncogene · doi:10.1038/onc.2010.332 · Cited by 114
Hug, B. A., & Lazar, M. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207674 · Cited by 112
Cited by
Acetyl coenzyme A: a central metabolite and second messenger
Pietrocola, F., Galluzzi, L., Bravo-San Pedro, J. M., Madeo, F., & Kroemer, G. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.014 · Cited by 1,378
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Functions and mechanisms of non-histone protein acetylation
Narita, T., Weinert, B. T., & Choudhary, C. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0081-3 · Cited by 1,232
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.